- Home
- TAK vs ALC Comparison
TAK vs ALC Comparison
Compare TAK & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- ALC
- Stock Information
- Founded
- TAK 1781
- ALC 1945
- Country
- TAK Japan
- ALC Switzerland
- Employees
- TAK N/A
- ALC N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- ALC Ophthalmic Goods
- Sector
- TAK Health Care
- ALC Health Care
- Exchange
- TAK Nasdaq
- ALC Nasdaq
- Market Cap
- TAK 44.4B
- ALC 46.8B
- IPO Year
- TAK N/A
- ALC N/A
- Fundamental
- Price
- TAK $15.03
- ALC $85.92
- Analyst Decision
- TAK
- ALC Buy
- Analyst Count
- TAK 0
- ALC 10
- Target Price
- TAK N/A
- ALC $107.00
- AVG Volume (30 Days)
- TAK 2.2M
- ALC 1.9M
- Earning Date
- TAK 05-08-2025
- ALC 05-13-2025
- Dividend Yield
- TAK 3.92%
- ALC 0.39%
- EPS Growth
- TAK N/A
- ALC 6.66
- EPS
- TAK 0.45
- ALC 2.25
- Revenue
- TAK $30,595,075,281.00
- ALC $9,925,000,000.00
- Revenue This Year
- TAK $1.01
- ALC $6.22
- Revenue Next Year
- TAK $1.04
- ALC $7.16
- P/E Ratio
- TAK $64.83
- ALC $38.03
- Revenue Growth
- TAK 7.45
- ALC 3.80
- 52 Week Low
- TAK $12.58
- ALC $80.48
- 52 Week High
- TAK $15.43
- ALC $101.10
- Technical
- Relative Strength Index (RSI)
- TAK 60.23
- ALC 36.60
- Support Level
- TAK $14.51
- ALC $84.94
- Resistance Level
- TAK $14.75
- ALC $87.64
- Average True Range (ATR)
- TAK 0.21
- ALC 1.64
- MACD
- TAK 0.09
- ALC -0.58
- Stochastic Oscillator
- TAK 99.66
- ALC 9.42
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About ALC Alcon Inc.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.